Issue Date | Title | Author(s) |
1-Jan-2014 | Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: The safety profile of deferasirox | Ali T. Taher; John B. Porter; Vip Viprakasit; Antonis Kattamis; Suporn Chuncharunee; Pranee Sutcharitchan; Noppadol Siritanaratkul; Raffaella Origa; Zeynep Karakas; Dany Habr; Zewen Zhu; M. Domenica Cappellini; American University of Beirut; UCL; Mahidol University; University of Athens; King Chulalongkorn Memorial Hospital, Faculty of Medicine Chulalongkorn University; Ospedale Regional Microcitemie; Istanbul Tip Fakultesi; Novartis Pharmaceuticals; Universita degli Studi di Milano |
1-Jan-2020 | Changing patterns in the epidemiology of β-thalassemia | Antonis Kattamis; Gian Luca Forni; Yesim Aydinok; Vip Viprakasit; National and Kapodistrian University of Athens; E.O. Ospedali Galliera; Faculty of Medicine, Siriraj Hospital, Mahidol University; Ege University Medical School |
1-Jan-2011 | Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload | Dudley J. Pennell; John B. Porter; Maria Domenica Cappellini; Lee Lee Chan; Amal El-Beshlawy; Yesim Aydinok; Hishamshah Ibrahim; Chi Kong Li; Vip Viprakasit; Mohsen Saleh Elalfy; Antonis Kattamis; Gillian Smith; Dany Habr; Gabor Domokos; Bernard Roubert; Ali Taher; Royal Brompton Hospital; UCL; Universita degli Studi di Milano; University of Malaya Medical Centre; Cairo University; Ege University Medical School; Kuala Lumpur Hospital; Prince of Wales Hospital Hong Kong; Mahidol University; Ain Shams University; University of Athens; Novartis Pharmaceuticals; Novartis International AG; American University of Beirut |
1-Jan-2014 | Current approach to iron chelation in children | Yesim Aydinok; Antonis Kattamis; Vip Viprakasit; Ege University Medical School; University of Athens Medical School; Mahidol University |
1-Jun-2013 | Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients | Ali T. Taher; John B. Porter; Vip Viprakasit; Antonis Kattamis; Suporn Chuncharunee; Pranee Sutcharitchan; Noppadol Siritanaratkul; Renzo Galanello; Zeynep Karakas; Tomasz Lawniczek; Dany Habr; Jacqueline Ros; Yiyun Zhang; M. Domenica Cappellini; American University of Beirut Medical Center; UCL Cancer Institute; Mahidol University; University of Athens; Chulalongkorn University; Ospedale Regional Microcitemie; Istanbul Tip Fakultesi; Novartis International AG; Novartis Pharmaceuticals; Universita degli Studi di Milano |
1-Nov-2013 | Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study | Ali T. Taher; John B. Porter; Vip Viprakasit; Antonis Kattamis; Suporn Chuncharunee; Pranee Sutcharitchan; Noppadol Siritanaratkul; Renzo Galanello; Zeynep Karakas; Tomasz Lawniczek; Dany Habr; Jacqueline Ros; Zewen Zhu; M. Domenica Cappellini; American University of Beirut; UCL; Mahidol University; University of Athens; Chulalongkorn University; Universita degli Studi di Cagliari; Istanbul Tip Fakultesi; Novartis International AG; Novartis Pharmaceuticals; Universita degli Studi di Milano |
1-Jun-2012 | Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major | Dudley J. Pennell; John B. Porter; Maria Domenica Cappellini; Lee Lee Chan; Amal El-Beshlawy; Yesim Aydinok; Hishamshah Ibrahim; Chi Kong Li; Vip Viprakasit; Mohsen S. Elalfy; Antonis Kattamis; Gillian Smith; Dany Habr; Gabor Domokos; Bernard Roubert; Ali Taher; Royal Brompton Hospital; UCL; Universita degli Studi di Milano; University of Malaya Medical Centre; Cairo University; Ege Universitesi; Kuala Lumpur Hospital; Prince of Wales Hospital Hong Kong; Mahidol University; Ain Shams University; University of Athens; Novartis Pharmaceuticals; Novartis International AG; American University of Beirut |
2-Aug-2012 | Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-Year results from a prospective, randomized, double-blind, placebo-controlled study | Ali T. Taher; John Porter; Vip Viprakasit; Antonis Kattamis; Suporn Chuncharunee; Pranee Sutcharitchan; Noppadol Siritanaratkul; Renzo Galanello; Zeynep Karakas; Tomasz Lawniczek; Jacqueline Ros; Yiyun Zhang; Dany Habr; Maria Domenica Cappellini; American University of Beirut; UCL; Mahidol University; University of Athens; Chulalongkorn University; Universita degli Studi di Cagliari; Istanbul Tip Fakultesi; Novartis International AG; Novartis Pharmaceuticals; Universita degli Studi di Milano |
1-Feb-2019 | Development of a patient-reported outcomes symptom measure for patients with nontransfusion-dependent thalassemia (NTDT-PRO <sup>©</sup> ) | Ali Taher; Vip Viprakasit; Maria Domenica Cappellini; Pranee Sutcharitchan; Richard Ward; Dalia Mahmoud; Abderrahmane Laadem; Anzalee Khan; Chad Gwaltney; Gale Harding; Kenneth Attie; Xiaosha Zhang; Jun Zou; Joseph Pariseau; X. Henry Hu; Antonis Kattamis; Evidera, USA; American University of Beirut Medical Center; Università degli Studi di Milano; Chulalongkorn University; Aghia Sophia Children's Hospital; Celgene Corporation; University of Toronto; Faculty of Medicine, Siriraj Hospital, Mahidol University; Nathan S. Kline Institute for Psychiatric Research; NeuroCog Trials; ERT; Acceleron Pharma |
18-Jun-2015 | Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload | Yesim Aydinok; Antonis Kattamis; M. Domenica Cappellini; Amal El-Beshlawy; Raffaella Origa; Mohsen Elalfy; Yurdanur Kilinç; Silverio Perrotta; Zeynep Karakas; Vip Viprakasit; Dany Habr; Niculae Constantinovici; Junwu Shen; John B. Porter; Ege University Medical School; University of Athens; Universita degli Studi di Milano; Cairo University; Universita degli Studi di Cagliari; Ain Shams University; Cukurova Universitesi; Child and of General and Specialist Surgery; Istanbul Tip Fakultesi; Mahidol University; Novartis Pharmaceuticals; Novartis International AG; UCL Cancer Institute |
11-Jan-2018 | Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: Results from a phase 2a study | Ali T. Taher; Zeynep Karakas; Elena Cassinerio; Noppadol Siritanaratkul; Antonis Kattamis; Aurelio Maggio; Stefano Rivella; Norbert Hollaender; Bruyere Mahuzier; Brian Gadbaw; Yesim Aydinok; American University of Beirut Medical Center; Università degli Studi di Milano; The Children's Hospital of Philadelphia; National and Kapodistrian University of Athens; Novartis Pharma S.A.S.; Istanbul Üniversitesi Tıp Fakültesi; Faculty of Medicine, Siriraj Hospital, Mahidol University; Novartis International AG; Ege University Medical School; Novartis Pharmaceuticals Corporation; UOSD MICI-A.O. Ospedali Riuniti “Villa Sofia-Cervello” Palermo |
1-Mar-2016 | Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study | Ali T. Taher; M. Domenica Cappellini; Yesim Aydinok; John B. Porter; Zeynep Karakas; Vip Viprakasit; Noppadol Siritanaratkul; Antonis Kattamis; Candace Wang; Zewen Zhu; Victor Joaquin; Marie José Uwamahoro; Yong Rong Lai; American University of Beirut Medical Center; Università degli Studi di Milano; Ege University Medical School; UCL; Istanbul Tip Fakultesi; Mahidol University; University of Athens; Novartis Pharmaceuticals; Novartis International AG; Guangxi Medical University |
26-Mar-2020 | A phase 3 trial of luspatercept in patients with transfusion-dependent β-thalassemia | M. Domenica Cappellini; Vip Viprakasit; Ali T. Taher; Pencho Georgiev; Kevin H.M. Kuo; Thomas Coates; Ersi Voskaridou; Hong Keng Liew; Idit Pazgal-Kobrowski; G. L. Forni; Silverio Perrotta; Abderrahim Khelif; Ashutosh Lal; Antonis Kattamis; Efthymia Vlachaki; Raffaella Origa; Yesim Aydinok; Mohamed Bejaoui; P. Joy Ho; Lee Ping Chew; Ping Chong Bee; Soo Min Lim; Meng Yao Lu; Adisak Tantiworawit; Penka Ganeva; Liana Gercheva; Farrukh Shah; Ellis J. Neufeld; Alexis Thompson; Abderrahmane Laadem; Jeevan K. Shetty; Jun Zou; Jennie Zhang; Dimana Miteva; Tatiana Zinger; Peter G. Linde; Matthew L. Sherman; Olivier Hermine; John Porter; Antonio Piga; l'Institut des Maladies Génétiques Imagine; Azienda Ospedaliera Brotzu - Microcitemico; Centre National de Greffe de Moelle Osseuse; University Hospital St. Marina; American University of Beirut Medical Center; Hopital Farhat Hached Sousse; UCSF Benioff Children‘s Hospital; Università degli Studi di Milano; National and Kapodistrian University of Athens; St.George University Hospital; Hôpital Necker Enfants Malades; Università degli Studi della Campania Luigi Vanvitelli; Laikon General Hospital; UCL; Rabin Medical Center Israel; St. Jude Children's Research Hospital; Celgene Corporation; E.O. Ospedali Galliera; Royal Prince Alfred Hospital; University of Toronto; Keck School of Medicine of USC; University of Malaya Medical Centre; Hospital Sultanah Aminah; Università degli Studi di Torino; Faculty of Medicine, Siriraj Hospital, Mahidol University; Ege University Medical School; National Health Service; National Taiwan University; Hippokration General Hospital; Chiang Mai University; Celgene; Hospital Umum; Ann and Robert H. Lurie Children's Hospital of Chicago; Specialized Hospital for Active Treatment in Oncology; Hospital Sultanah Bahiyah; Acceleron Pharma |
1-Oct-2019 | Quality of life in patients with β-thalassemia: A prospective study of transfusion-dependent and non-transfusion-dependent patients in Greece, Italy, Lebanon, and Thailand | Maria Domenica Cappellini; Antonis Kattamis; Vip Viprakasit; Pranee Sutcharitchan; Joseph Pariseau; Abderrahmane Laadem; Valerie Jessent-Ciaravino; Ali Taher; American University of Beirut Medical Center; Università degli Studi di Milano; King Chulalongkorn Memorial Hospital, Faculty of Medicine Chulalongkorn University; Aghia Sophia Children's Hospital; Celgene Corporation; Faculty of Medicine, Siriraj Hospital, Mahidol University |
1-Feb-2021 | Revisiting the non-transfusion-dependent (NTDT) vs. transfusion-dependent (TDT) thalassemia classification 10 years later | Khaled M. Musallam; Maria D. Cappellini; Vip Viprakasit; Antonis Kattamis; Stefano Rivella; Ali T. Taher; American University of Beirut Medical Center; Università degli Studi di Milano; National and Kapodistrian University of Athens; Penn Medicine; Faculty of Medicine, Siriraj Hospital, Mahidol University; International Network of Hematology |
1-Apr-2010 | Tailoring iron chelation by iron intake and serum ferritin: The prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias | Maria Domenica Cappellini; John Porter; Amal El-Beshlawy; Chi Kong Li; John F. Seymour; Mohsen Elalfy; Norbert Gattermann; Stéphane Giraudier; Jong Wook Lee; Lee Lee Chan; Kai Hsin Lin; Christian Rose; Ali Taher; Swee Lay Thein; Vip Viprakasit; Dany Habr; Gabor Domokos; Bernard Roubert; Antonis Kattamis; Universita degli Studi di Milano; UCL; Cairo University; Prince of Wales Hospital Hong Kong; Peter Maccallum Cancer Centre; Ain Shams University; Heinrich Heine Universitat; Hopital Henri Mondor; The Catholic University of Korea; University of Malaya Medical Centre; National Taiwan University Hospital; Hopital Saint-Vincent-de-Paul; American University of Beirut; King's College London; Mahidol University; Novartis Pharmaceuticals Corporation; Novartis International AG; University of Athens |
1-Feb-2019 | Validation of a patient-reported outcomes symptom measure for patients with nontransfusion-dependent thalassemia (NTDT-PRO <sup>©</sup> ) | Ali Taher; Maria Domenica Cappellini; Vip Viprakasit; Pranee Sutcharitchan; Dalia Mahmoud; Abderrahmane Laadem; Anzalee Khan; Chad Gwaltney; Gale Harding; Kenneth Attie; Xiaosha Zhang; Jun Zou; Joseph Pariseau; X. Henry Hu; Antonis Kattamis; Evidera, USA; American University of Beirut Medical Center; Università degli Studi di Milano; Chulalongkorn University; Aghia Sophia Children's Hospital; Celgene Corporation; Faculty of Medicine, Siriraj Hospital, Mahidol University; Nathan S. Kline Institute for Psychiatric Research; NeuroCog Trials; ERT; Acceleron Pharma |